ArticleJournal of gastrointestinal oncology2025
Survival of hepatectomy in colorectal cancer patients with ten or more liver metastases: a retrospective cohort study of multidisciplinary treatment.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maximizing the "toolbox" for patients with initially unresectable colorectal liver metastases: have liver mets "met" their match?Journal of gastrointestinal oncology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Palliative chemotherapy is the standard first treatment for patients with ≥10 liver metastases, irrespective of resectability. This study aimed to assess the clinical benefits of hepatic resection and identify optimal treatments for colorectal cancer patients with ≥10 liver-limited metastases (LLMs). Methods: A retrospective study of 373 patients with unresectable colorectal cancer and ≥10 liver metastases. Patients were grouped into hepatic surgery ± radiofrequency ablation (RFA) + systemic therapy, RFA + systemic therapy, and systemic therapy alone. Kaplan-Meier and Cox proportional hazards methods were used to analyze overall survival (OS) and progression-free survival (PFS). A nomogram was developed and validated. Results: Three-year survival rates were 39.2%, 18.6%, and 8.2% for surgery ± RFA + systemic, RFA + systemic, and systemic only groups, respectively. Significant survival differences were noted in both Conclusions: Hepatectomy, with or without RFA, is associated with significantly improved survival in selected patients with ≥10 liver metastases. Further prospective studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.